Oct 6, 2025 · Harrow is redefining the standard of care in eyecare with a portfolio of trusted, high-value pharmaceutical solutions that deliver proven safety, efficacy, and affordability.

Harrow, a leading provider of ophthalmic disease management solutions in North America, was founded with a commitment to deliver safe, effective, accessible, and affordable medications …

Harrow was established with the core principle of delivering accessible eyecare solutions to both eyecare providers and patients. We are dedicated to helping eligible patients access the …

By selectively investing in assets with reduced clinical and regulatory uncertainty and executing with a streamlined operational model, Harrow efficiently progresses products toward approval …

Harrow INC SEC filing: Form 8-K iXBRL on 09/09/2025 (0001493152-25-012840).

The content provided by Harrow on this web site and all site-related services is intended to educate and inform you about Harrow, our product candidates and our technology.

The Investor Relations website contains information about Harrow, Inc.'s business for stockholders, potential investors, and financial analysts.

SAN DIEGO , May 5, 2016 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary …

Harrow continues to be a reliable and innovative pharmaceutical supplier to hundreds of thousands of Americans and many thousands of eyecare institutions across the country, …

Nov 13, 2019 · Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including ImprimisRx, the nation’s leading ophthalmology outsourcing facility and …